Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Extended 2-dose Regimens of 9vHPV Vaccine
NCT04708041Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Primary completion
- Oct 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Merck & Co.. Started Mar 2021; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT04708041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708041.